title: Prevention of calcineurin inhibitor nephrotoxicity in renal transplantation.
abstract: Calcineurin inhibitors (CNI) cyclosporine (Csa) and tacrolimus (Tac) are now first intention immunosuppressive drugs in renal transplantation. However, although these treatments are effective for preventing allograft rejection, they are nephrotoxic: they can cause chronic renal dysfunction and degradation of renal graft function [Nankivell BJ, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003 Dec 11;349(24):2326-33]. In view of these undesirable effects, several strategies have been developed to minimize or even avoid their use. These strategies are reviewed and discussed in this paper.
authors.affiliation: Nephrology Department, Université Paris Sud, France.
authors.forename: A
authors.initials: A
authors.lastname: Jacquet
authors.forename: H
authors.initials: H
authors.lastname: Francois
authors.forename: C
authors.initials: C
authors.lastname: Frangie
authors.forename: L
authors.initials: L
authors.lastname: Ahmad
authors.forename: B
authors.initials: B
authors.lastname: Charpentier
authors.forename: A
authors.initials: A
authors.lastname: Durrbach
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000077552:Basiliximab; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D006084:Graft Rejection / Q000188:drug therapy; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000209:etiology / Q000517:prevention & control*; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000911:Antibodies, Monoclonal; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D016559:Tacrolimus